Risk of neurodevelopmental disorders associated with paternal use of valproate during spermatogenesis: a living meta-analysis-version 1.
J Neurol Neurosurg PsychiatrySep 14, 2026 (epub)
Jakob Christensen, Betina B Trabjerg, Marleen M H J van Gelder et al.
✦ AI-curated · Sources linked
In 30 seconds
This living meta-analysis evaluated the association between paternal use of valproate during spermatogenesis and the risk of neurodevelopmental disorders (NDDs) in offspring, compared to lamotrigine or levetiracetam. The analysis included data from three studies across Norway, Sweden, and Taiwan. The pooled hazard ratios for NDDs were 1.05 and 1.03, indicating no significant increase in risk associated with valproate use.
Key findings
- Pooled HR for NDDs with valproate vs lamotrigine/levetiracetam was 1.05 (95% CI 0.87 to 1.27).
- Pooled HR for NDDs in another analysis was 1.03 (95% CI 0.85 to 1.24).
- No significant increase in NDD risk was found with paternal valproate exposure.
Why it matters
Understanding the potential risks associated with paternal medication use during spermatogenesis is crucial for informing treatment decisions and counseling patients regarding reproductive health and offspring outcomes.